Intrexon | XON - Operating Profit

Stock Price
3.31
Daily Change
-0.25 -6.90%
Monthly
-22.96%
Yearly
76.74%
Q1 Forecast
3.67

Intrexon reported $-60.84M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Agenus USD -13.31M 12.58M Mar/2025
Alaunos Therapeutics USD -1.19M 432K Sep/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD -4.28M 32.1M Mar/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Incyte USD 383.88M 47.43M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
MannKind USD -69.24M 28.19M Dec/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025